ChiCTR2100052094 版本V1.5 版本创建时间2022/04/27 11:11:42 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052094 

最近更新日期:

Date of Last Refreshed on:

2022-04-27 11:07:06 

注册时间:

Date of Registration:

2021-10-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

直肠模块化解剖在男性低位直肠癌保肛根治性手术中的应用

Public title:

Modular total mesorectal excision in anus-preserving radical surgery for low rectal cancer male patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

直肠模块化解剖在男性低位直肠癌保肛根治性手术中的应用

Scientific title:

Modular total mesorectal excision in anus-preserving radical surgery for low rectal cancer male patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈伟杰 

研究负责人:

林国乐 

Applicant:

Chen Weijie 

Study leader:

Lin Guole 

申请注册联系人电话:

Applicant telephone:

+86 13521624987

研究负责人电话:

Study leader's
telephone:

+86 10 69152310

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wedge.c@163.com

研究负责人电子邮件:

Study leader's E-mail:

cwj022303019@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区帅府园1号

研究负责人通讯地址:

北京市东城区帅府园1号

Applicant address:

1 Shuaifu Garden, Dongcheng District, Beijing

Study leader's address:

1 Shuaifu Garden, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京协和医院

Applicant's institution:

Peking Union Medical College Hospital

研究负责人所在单位:

北京协和医院

Affiliation of the Leader:

Peking Union Medical College Hospital

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京协和医院

Primary sponsor:

Peking Union Medical College Hospital

研究实施负责(组长)单位地址:

北京市东城区帅府园1号

Primary sponsor's address:

1 Shuaifu Garden, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

东城区

Country:

China

Province:

Beijing

City:

Dongcheng District

单位(医院):

北京协和医院

具体地址:

帅府园1号

Institution
hospital:

Peking Union Medical College Hospital

Address:

1 Shuaifu Garden

经费或物资来源:

中国医学科学院

Source(s) of funding:

Chinese Academy of Medical Sciences

研究疾病:

直肠癌  

Target disease:

Rectal cancer

研究疾病代码:

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

通过大样本数据验证RMD的有效率,进而形成手术操作规范,推广普及将男性低位直肠癌根治术的治疗均质化;形成低位直肠癌男性患者术中情况及预后的数据库,便于建立低位直肠癌男性患者的预测模型。  

Objectives of Study:

To verify the effectiveness of RMD, and then to formulate surgical procedures, popularize and popularize the treatment of men with low rectal cancer radical resection; to form a database of intraoperative conditions and prognosis of male patients with low rectal cancer, so as to facilitate the establishment of predictions for male patients with low rectal cancer model.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 内镜及肛诊肿瘤下缘距离肛缘小于7cm,且大于3cm。此类患者属于低位直肠癌患者,涉及保留肛门、生殖功能等问题;
2. 直肠MRI评估肿瘤可行根治性手术切除,即TNM分期小于T2N0M0,或T3及N1以上接受过新辅助治疗患者;
3. 男性患者。

Inclusion criteria

1. Patients with the distance between the lower edge of the tumor and the anal edge less than 7 cm and greater than 3 cm, such tumors belong to low rectal cancers, the patients involve anal retention, reproductive function and other problems;
2. Patients with TNM stage less than T2N0M0;
3. Male patients.

排除标准:

1. 术中发现腹腔种植转移等原因,无法手术患者;
2. 器官移植患者,接受过或正在接受免疫治疗的患者;
3. 精神、心理等各种原因无法接受随访患者;
4. 不愿参与课题研究者。

Exclusion criteria:

1. The patients were unable to be operated due to intraoperative reasons such as abdominal implantation metastasis;
2. Organ transplant patients, patients who have received or are receiving immunotherapy;
3. Mental, psychological and other reasons can not accept follow-up patients;
4. Unwilling to participate in the project researchers.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2021-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-01 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

70

Group:

Group 1

Sample size:

干预措施:

直肠模块化解剖

干预措施代码:

Intervention:

RMD(rectal modular dissection)

Intervention code:

组别:

1组

样本量:

70

Group:

Group 2

Sample size:

干预措施:

传统直肠低位前切除术+全直肠系膜切除术

干预措施代码:

Intervention:

LAR(low anterior rectal resection) and TME(total mesorectal excision)

Intervention code:

组别:

经肛门TME手术组

样本量:

60

Group:

Transanal TME group

Sample size:

干预措施:

经肛门TME手术

干预措施代码:

Intervention:

Transanal TME

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

东城区 

Country:

China

Province:

Beijing

City:

Dongcheng District

单位(医院):

北京协和医院 

单位级别:

三甲 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

标本质量

指标类型:

主要指标

Outcome:

Quality of the specimen

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者预后

指标类型:

主要指标

Outcome:

Prognosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围手术期情况

指标类型:

主要指标

Outcome:

Perioperative situation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨盆情况

指标类型:

主要指标

Outcome:

Pelvic condition

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 30 years
最大 Max age 80 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

队列研究,无随机

Randomization Procedure (please state who generates the random number sequence and by what method):

not involved, the study is a cohort study.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

读者要求,可发送

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Readers request, the data can be sent

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质CRF表以文件形式保存,整理的电子数据保存在百度网盘中

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper CRF tables are saved in the form of files, and the sorted electronic data is saved in Baidu web disk.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-17 15:00:43